Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.
Filter by yearAll 2022 2021 2020 2019 2018 2017 2016 2015 2014 2012 2011 2010 2009 2008 2007 2006 2005 2001 2000 1998 1997 1996 1995 1994 1993 1992 1991 1990 1988 1986 1985
Gauthier, S, et al. (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomized, controlled, double-blind, parallel-arm, phase 3 trial. Available at: The Lancet
Lai, R.Y.K., et al. (2016) Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease. Available at: Biomolecules
Rickard, J. E., et al. (2016) Assays for the Screening and Characterization of Tau Aggregation Inhibitors. Available at: Tau Protein.
Šimic, G, et al. (2016) Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Available at: Biomolecules
Vuksanovic V, Staff RT, Ahearn T, et al. (2016) Frontotemporal atrophy and clinical estimates of disease severity in behavioural variant frontotemporal dementia: The role of cognitive reserve. Presented at the Alzheimer’s Research UK Conference, Manchester, UK.